Reddit Posts
Mentions
I see both getting to -70% IgA reduction with higher/longer dosing. At single dose CLYM can do -70% at 6mg/kg SC and JADE101 needs more than 10mg/kg SC to get there on a single dose. (attached is side-by-side comparison) Possibly CLYM has better bioavailability at SC or more potent? Both drugs still look more potent than sibe in NHP since even at 30mg/kg IV sibe only gets -55% IgA at nadir from JBIO data and CLYM showed sibe 100mg/kg SC is still only -65% https://preview.redd.it/k7md01prwrag1.png?width=2704&format=png&auto=webp&s=c274bf841de4663370f136abb451d45c6e06b2e0
CLYM and JBIO have both shown IgA reductions in preclinical models. you can see the nadir of CLYM is more reduction than JBIO. GRANTED clym is dosing higher.
>CLYM has shown significantly MORE POTENT results than JBIO Hold up, I understand the longer half-life but how do you get more potent results than JBIO? What data are you looking at? If you're right it's more potent then it should be trading higher than JBIO and we should be adding into the CLYM and JBIO Phase 1 readouts because it will be clear CLYM is better
Does it make sense that it's a bet on CLYM116 for IgAN? JBIO's FIH HV data will be in 1H26 and CLYM116 in mid-2026, so very similar timelines. JBIO is being valued at $1.25B cap and CLYM still far less than that. JBIO has said there are 3 things that differentiate it from the current gen anti-APRIL drugs. 1) half-life. Well CLYM116 has a similar half life at 24.2 days with JBIO at 27 days. 2) prevention of large immune complexes: CLYM actually has shown their data on this and JBIO hasn't yet 3) efficacy: from the NHP data it looks similar with both drugs a bit over 70% decline in IgA but arguably CLYM gets there faster. JBIO needs 30mg/kg to get there and CLYM116 only needs 6mg/kg SC. And the mechanism is different with degrading APRIL vs very high affinity so who knows which mechanism wins out. I think it's possible it's a hedge against JBIO's readout. RA participated in the JBIO's Oct PIPE and own 10% so RA is betting on both horses...
Where are you u/IJesusChrist ? Something is happening with $CLYM but I'm not sure what!
They are researching two main drug candidates: budoprutug and CLYM116, both monoclonal antibodies for various immune-mediated diseases. But I don't know if there's any positive news yet.
is CLYM that new drug for chlamydia?
Plz, someone explain the catalyst for the CLYM?
TipRanks recommended CLYM a few weeks back. Looking good so far!
I’m looking at playing CLYM for the day.
\> ($CLYM): CLYM Major Shareholder RA Capital in $39M Stock-for-Warrant Swap You guys still holding?
Not doing badly! Thanks Climb Bio $CLYM https://preview.redd.it/rmgf3yh8xt6g1.png?width=1065&format=png&auto=webp&s=41c1ae8c28ec5033002ae1e3b0d612b498ab605c
ehh, ITP and Lupus data expected in H2 2026... it's a waiting game now for CLYM. They confirmed subcutaneous (SC) formulation initial data in H1 2026. $175M cash.
Climb Bio is presenting CLYM116 (albeit already known) data on 8 November. If they surprise with something it might be a decent catalyst to get in on. Thoughts?
CGEM and CABA mooning today but CLYM goes \*chirp chrip\* PAIN! The market doesn't think antibodies are enough and will need bispecifics and CAR-Ts :|
I averaged up a bit and now own approx 750k shares. At $140million market capitalization WHAT CAN GO WRONG? Just let CLYM get to ZBIO's valuation. Let's gooo Do you really think the valuation discrepancy from ZBIO is because CLYM doesn't have any catalysts for a while until 2026? Any view on why AI ETI LLC dumped all their shares?
The fact that CLYM isnt getting any attention is laughable. Bought at 1.20 and expecting to get to to 4 dollars by end of year
You should look at CLYM. It isn’t going to go bonkers but it’s probably the best deal I’ve ever seen in biotech. Same guy ijesuschrist had ELEV at 0.4 and we sold for $3 after 6mo
both drugs target the same protein, CD19. So proof of concept of zbio "working" is proof of concept that CLYM will work. honestly I would like to see clym add MS to their pipeline. I think the stock would move up a lot if they announced that because CLYM drug is likely going to be given once every SIX MONTHS whereas you get the same or worse efficacy with zbio and it requires a needle every WEEK
Thanks for the DD. I’m interested in the technology and their initial readouts are positive. Question: You mention MS applications for the drug, but their company site, pipeline, and plans make no mention. Why are you comparing CLYM to ZBIO for MS?
Yeah I'm in for 580 shares, checked your profile and you were right about $KALA and $CLYM so I hope you're right about this too!
I like these . ACHR Archer Aviation, CLYM Climb Bio
CLYM -- +71% since my August 4's post.
$CLYM continues to march higher... up 45% since I highlighted it earlier this month. Hope you joined the ride. You can see the original post here: [https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer\_says\_clym\_will\_rally\_to\_10\_its\_at\_15/](https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer_says_clym_will_rally_to_10_its_at_15/)
$CLYM continues to climb @ $1.83 --- it was @ $1.45 when I highlighted it 10 days ago --- [https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer\_says\_clym\_will\_rally\_to\_10\_its\_at\_15/](https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer_says_clym_will_rally_to_10_its_at_15/)
CLYM is easily worth 12-15 if Budoprutug is remotely superior to Uplizna. The buyer of CLYM will have the best / standard of care Lupus drug. The problem with this company is that no IB will push it because they shunned banks when RA reverse merged the drug into them from their incubator
CLYM is up 20% since I posted about it on Saturday night.... [https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer\_says\_clym\_will\_rally\_to\_10\_its\_at\_15/](https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer_says_clym_will_rally_to_10_its_at_15/)
CLYM & LDI . Both are a must if you wanna make a ton of money this year. Especially if you are patient
I don't see any reason why it's CLYM is up 20% this morning with that much volume but well played OP
CLYM -- +20%. For those who missed my yesterday's post -- [https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer\_says\_clym\_will\_rally\_to\_10\_its\_at\_15/](https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer_says_clym_will_rally_to_10_its_at_15/)
CLYM -- +18% this morning. For those who missed my yesterday's post --https://www.reddit.com/r/pennystocks/comments/1mgvawy/oppenheimer\_says\_clym\_will\_rally\_to\_10\_its\_at\_15/
CLYM -- +18% this morning @ 1.7....
CLYM & BTAI showing some life
I like CLYM long term, no idea if they have a catalyst this week tho
How do we feel this coming week for NVNI - TNFA - PSTV - CGTX - CLYM? Thank you as always !
Keep CLYM on your radar tomorrow morning – it might be gearing up for a breakout.
Keep CLYM on your radar tomorrow morning – it might be gearing up for a breakout.
CLYM going up for no apparent reason but I'll take it. Also in NVNI let's go to .85
LXRX, CLYM and ENVB all up good day for biotech
CLYM doing things up 6% on low volume
De-risked + misunderstood = potential goldmine… or just ignored for a reason. If the science holds up, $CLYM could be a sleeper hit.
$CLYM shows real potential with its twice-a-year dosing and subcutaneous delivery. If 2026 clinical data is good, this could jump.
$CLYM looks like a classic undervalued biotech gem with solid fundamentals and a de-risked mechanism. The twice-yearly dosing and subcutaneous delivery could be real differentiators in a crowded autoimmune space. The messy reverse merger and low analyst coverage explain the discount, but the clinical timeline and cash position make it worth watching closely. If lupus data in 1H26 is positive, this could be a sleeper hit. Risk seems manageable with potential upside significant definitely one to keep on the radar!
Synopsis Climb Bio Inc. (CLYM) is a clinical-stage biotechnology company with a robust pipeline targeting immune-mediated diseases. The company has secured FDA clearance for trials in multiple indications, including Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE). With a strong cash position expected to fund operations through 2027, Climb Bio is well-positioned to advance its clinical programs. However, investors should be mindful of the inherent risks associated with clinical-stage biotech companies, such as regulatory approvals and market competition. Market Analysis Technical Outlook: The stock is trading at $1.28, with a slight increase of $0.04 (3.18%) from the previous close. The 5-day moving average is $1.23, indicating a bullish trend. The Relative Strength Index (RSI) is 55.90, suggesting neutral momentum. The Moving Average Convergence Divergence (MACD) is positive, further supporting a bullish outlook. Risk Factors: Key risks include the uncertainties inherent in clinical trials, potential regulatory hurdles, and competition from other biotech firms. Additionally, the company's net loss of $73.9 million for the full year 2024, primarily due to acquired in-process research and development expenses, indicates ongoing financial challenges. Key Metrics: The company reported a cash position of approximately $213 million as of December 31, 2024, providing a runway through 2027. The market capitalization is $79.739 million, with shares outstanding totaling 67.58 million. The 52-week range is $1.05 to $9.21, reflecting significant volatility. Market Sentiment: Analyst sentiment is positive, with a consensus 'Buy' rating and a 12-month price target of $10, suggesting a potential upside of approximately 726%. However, the stock has experienced a decline of 82.98% over the past year, indicating market volatility and investor caution. https://preview.redd.it/wlawkjochpaf1.jpeg?width=1070&format=pjpg&auto=webp&s=d2dcae03e6bb1bff500551fdd08c6aec099f2e5b
We press on! CLYM making some movement today
As of March 31, 2025, Climb Bio (CLYM) had $197.8 million in cash, cash equivalents, and marketable securities on hand. This amount is expected to fund the company’s operations through 2027.
Ya I'm in that and CLYM both long holds for me
How are you feeling about CLYM now? Saw some movement today, looking forward to a write up as well.
CLYM will be a 10-12 stock this time next year
Are you typically focused on biotech stocks? CLYM doesn’t seem like it’s going anything going for it. I’ll look forward to a write up, but I’m not sure the risk/reward could possibly be attractive.
I think the company could be worthless But there is a lot of tax loss selling, especially in this name because of all the institutions which are piled into it I personally don’t have a position I am buying CLYM. I believe they will be a leader in nephrology the stock currently trades at a huge discount to the cash and book value. I will do a write up, but the stock is being punished unfairly due to RA Capital having a huge position and the reverse merger being facilitated by investment banks, which now cannot cover the stock and therefore the stock gets zero visibility by huge funds. I’m to believe that RA might be short the stock against the box using the shares they own to benefit in another fund with another custodian, but I can’t be certain Do your own due diligence I will also do a write up later maybe closer to the end of the year I’m down about continuing to buy I’ve had some life expenses come up and gone on a few vacations since this trade I’m still up about 130 140% on my personal account to date. My peak was over 180%.